Meridian Medical Technologies, a unit of CDMO Kindeva, snared a $129 million contract to supply the United States with the chemical nerve agent antidote autoinjector DuoDote.
The FDA-approved, dual-chamber autoinjector contains atropine and pralidoxime chloride and is used to counteract the effects of organophosphorus nerve agents and insecticides, the company said in a Jan. 16 press release.
Kindeva, a CDMO focused on drug delivery devices, said the DuoDote autoinjectors will be produced and distributed from its fill-finish facility in St. Louis.
“This contract underscores the ongoing importance of maintaining readiness against potential threats,” Milton Boyer, Kindeva’s chief executive, said in the release. “With our extensive experience in this space, we are proud to continue supporting the U.S. government’s efforts to protect public health and safety.”
Kindeva operates manufacturing and R&D facilities in the U.S. and U.K.
Last year, the company secured a 33 million pound sterling ($42.1 million at the time) contract from the U.K.’s Life Sciences Innovation Manufacturing Fund to boost its inhaler production and sustainability efforts.
The grant was part of the country’s move to support the development and production of inhalers that utilize new propellants with lower global warming potential.